Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

22 Trials of atacicept, which blocks the activity of two B-cell survival factors, BAFF and APRIL were terminated prematurely in phase II/III due to safety concerns; however, the data showed a trend to benefit for the higher dose tested. 23 Studies of B cell-directed agents continue, with modifications to improve efficacy, such as obinutuzumab, an anti-CD20 mAb engineered for enhanced cytotoxicity ( NCT02550652 ).
tujafilina population analyzed in the present study, a statistical analysis of the absolute copy numbers of gro EL and atp D revealed that although both endosymbiotic bacteria showed a trend line with a positive slope (0.0540 for B. aphidicola BCt; 0.0296 for S. symbiotica SCt; Fig. 4B ), a significant positive correlation was only observed between the average temperature recorded and the amount of B. aphidicola BCt ( p =0.002).
44,45 Overexpression of WAVE1-A and WAVE1-B (but not WAVE1-C) showed a trend toward increasing the expression of embryonic genes, while knockdown of WAVE1 in embryos through MO-injections caused a downregulation of many genes, including hox genes, indicating that nuclear WAVE1 plays a role in embryonic development ( Fig. 2G ). 45 Co-immunoprecipitation experiments with nuclear extracts of an NLS-WAVE1–A or –B fusion protein were conducted to identify nuclear WAVE1 interactors.
Histone deacetylase inhibitors Entinostat is a histone deacetylase inhibitor that has been studied in a Phase II trial in combination with exemestane, which showed a trend for prolonged PFS versus exemestane alone in patients with HR-positive metastatic breast cancer progressing during NSAI therapy (4.3 months vs 2.3 months; HR, 0.73; P =0.055); in an exploratory end point, patients receiving entinostat therapy showed improved median OS compared with those receiving exemestane alone (28.1 months vs 19.8 months; P =0.036). 37 A Phase III trial of entinostat plus exemestane in patients with recurrent HR-positive advanced breast cancer who have relapsed or have progressive disease on prior NSAI therapy is under way ( NCT02115282 ).